Compare CATY & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CATY | CELC |
|---|---|---|
| Founded | 1962 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 1996 | 2017 |
| Metric | CATY | CELC |
|---|---|---|
| Price | $47.33 | $113.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $52.75 | ★ $106.63 |
| AVG Volume (30 Days) | 342.7K | ★ 527.9K |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | ★ 14.94 | N/A |
| EPS | ★ 4.54 | N/A |
| Revenue | ★ $53,793,000.00 | N/A |
| Revenue This Year | $20.37 | N/A |
| Revenue Next Year | $5.41 | N/A |
| P/E Ratio | $10.52 | ★ N/A |
| Revenue Growth | ★ 2.93 | N/A |
| 52 Week Low | $36.06 | $7.58 |
| 52 Week High | $54.99 | $120.32 |
| Indicator | CATY | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 31.14 | 55.98 |
| Support Level | $44.58 | $97.75 |
| Resistance Level | $49.21 | $114.54 |
| Average True Range (ATR) | 1.36 | 5.14 |
| MACD | -0.43 | 0.36 |
| Stochastic Oscillator | 20.58 | 63.40 |
Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities and advisory services.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.